Bluebird bio to cut 25% of jobs in fresh bid to battle cash crunch ... will begin to roll out a gene therapy from Vertex Pharmaceuticals and CRISPR Therapeutics to treat rare blood disorder ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...